CFDE Data Portal | Search HS1BP3-IT1

	Label	Description
	HS1BP3-IT1 associations Collection (Entity type)	Associations for HS1BP3-IT1_associations
	HS1BP3-IT1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	HS1BP3-IT1 Gene (Entity type)	ENSG00000231948 - HS1BP3 intronic transcript 1
	GSE226249 pirfenidone HL 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE184210 0 V 1 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 12 V 6 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

HS1BP3-IT1 associations

Associations for HS1BP3-IT1_associations

HS1BP3-IT1 associations.tsv

A file from IDG as part of the Harmonizome project

HS1BP3-IT1

ENSG00000231948 - HS1BP3 intronic transcript 1

GSE226249 pirfenidone HL 0 v 7 human dn

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

A Gene Set from LINCS

GSE184210 0 V 1 GLUCAGON MOUSE UP

A Gene Set from LINCS

GSE158834 12 V 6 PALMITIC ACID HUMAN UP

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.